Portfolio Details

Blue Matter

---

Blue Matter is a strategic consulting firm serving the life sciences industry. From its offices in North America, Europe and Asia, Blue Matter serves pharmaceutical and biotech companies from around the globe. The firm helps clients maximize value at the product, portfolio, and organization levels. It has broad therapeutic expertise with a focus on complex markets such as oncology, CNS and rare diseases.

Since Baird Capital’s initial investment in 2020, Blue Matter has expanded its platform, delivered approximately 25% organic CAGR growth, executed three add on acquisitions and more than tripled its revenue. In 2026 Baird Capital closed a single asset continuation vehicle to support the company’s next stage of growth, including a focus on scaling and deepening its capabilities in medical communications, market access communications, patient services, and market research and analytics to supplement its core strategy consulting business.

“Baird Capital has been a highly committed and trusted partner to Blue Matter throughout our growth journey. The continuation of our relationship through this transaction reflects our shared long-term vision to build Blue Matter into the premier strategic consulting partner for life sciences companies commercializing innovations that meaningfully extend and improve human life.”

Since our investment Blue Matter has completed three add-on acquisitions, strengthening the company’s capabilities and broadening its service offerings:

European based provider of specialist supply chain expertise, adding a complimentary customer base and management expertise to Blue Matter’s offerings.

Leading integrated healthcare communications and PR agency focused on corporate, clinical and commercial communications for the pharma and life sciences industry.

Biopharma-focused analytics firm expanding Blue Matter’s Insights team which provides primary market research, data analytics, and technology services to biopharma clients.

 

Initial investment: September 2020 | Reinvested: April 2026

Investment Contacts

---

Learn more about the company